Ambrisentan (Myogen).
Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly BASF Pharma), for the potential treatment of post-ischemic acute renal failure and cardiovascular disease . By August 2001, ambrisentan had entered phase II trials for chronic heart failure, hypertension, kidney failure and pulmonary hypertension.
Billman
George E
GE
Department of Physiology and Cell Biology The Ohio State University, Columbus 43210-1218, USA. billman.1@osu.edu
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D015195:Drug Design; D065128:Endothelin Receptor Antagonists; D006801:Humans; D010666:Phenylpropionates / Q000138:chemical synthesis / Q000494:pharmacology*; D011724:Pyridazines; D044022:Receptor, Endothelin A; D013329:Structure-Activity Relationship
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D010666:Phenylpropionates; D011724:Pyridazines; D044022:Receptor, Endothelin A; C467894:ambrisentan